Aktuellt
SENASTE
Redeye anticipates a muted Q2 2024 in terms of quarter-on-quarter growth, though stable ARR growth is expected both year-on-year and quarter-on-quarter from Physitrack. While the strong performance of the Lifecare division is forecasted to continue, overall growth is expected to be held back by the Wellness division. Physitrack’s Q2 2024 report is set to be released on 13 August at 08:00, followed by a conference call at 10:00. We maintain our fair value range with a Base case valuation of SEK35 per share.
LÄS MER
